Andrew Alliance is a Swiss-based company that develops, produces, and sells products and services in life sciences and laboratory automation.
Andrew Alliance products are used in academic and industrial research laboratories, e.g. in companies in the pharmaceutical, biotech, chemical, and food industries.
They are also used in laboratories that perform clinical or environmental analysis, in forensic laboratories, and in industrial laboratories where industrial process analysis, production, and quality assurance are performed.
The primary product is a cloud-deployable software solution known as “OneLab”, along with an ecosystem of connected devices that allows “any scientist to design and execute laboratory protocols efficiently”. Connected devices are programmed and controlled via OneLab software through an Ethernet or Wi-Fi connection based on an Internet of Things architecture.
Andrew Alliance was founded in 2011 in Geneva, Switzerland.
In 2013, The company presented at the Society for Laboratory Automation and Screening conference in Orlando, USA, the first benchtop robot using conventional mechanical pipettes: Andrew.
In 2014 Andrew Alliance secured a series B financing round from Omega Funds, a healthcare fund specializing in late-stage life science investments, to develop commercial operations in the U.S. market.
They completed 2018 a C funding round of 14 million dollars of investments from several enterprises in the life sciences. Some participants of this round include Tecan Group, Inpeco, and Waters Corporation.
In 2019, Andrew Alliance launched the market Andrew+, Pipette+, and OneLab at the Society for Laboratory Automation and Screening conference in Washington, D.C., USA.
In January 2020, Waters Corporation acquired Andrew Alliance.